

Big Bets. Bold Research. Best Outcomes.

At the Parker Institute for Cancer Immunotherapy, we imagine a world where cancer is curable. We are making this a reality by transforming the way research is done. We bring together the top minds in cancer immunotherapy. We fund the boldest ideas that will lead to breakthrough discoveries. And we give our researchers the most innovative tools and resources to fuel their work. Our goal: *to accelerate the development of breakthrough immune therapies to turn cancer into a curable disease.*

By the numbers



7 Research
Institutions



40+ Industry & Nonprofit
Collaborations



170+ PICI
Researchers



4 Clinical Trials



60+ Labs



9 Scholars, Bridge
Scholars and Fellows

We started by providing institutional support to Memorial Sloan Kettering Cancer Center, Stanford Medicine, The University of California, Los Angeles, The University of California, San Francisco, The University of Pennsylvania, and The University of Texas MD Anderson Cancer Center. We also provide programmatic support for outstanding investigators, including a talented group of researchers at Dana-Farber Cancer Institute, Robert Schreiber, PhD, of Washington University School of Medicine in St. Louis, Nina Bhardwaj, MD, PhD, of the Icahn School of Medicine at Mount Sinai and Phil Greenberg, MD, of the Fred Hutchinson Cancer Research Center.

Make big bets to make the biggest impact

The Parker Institute **funds high-risk, high-reward research projects** in areas that hold the most promise for advancing cancer immunotherapy and helping patients.



- **Best-in-class T-cells:** We advance the next generation of T-cell therapies to provide targeted, safe, long-lasting treatments that can conquer cancer.
- **Checkpoint Blockade Response:** We uncover why some patients respond to immunotherapy while others may not to overcome cancer drug resistance.
- **Tumor Antigen Discovery:** We pinpoint novel cancer cell markers that will become the foundation for new therapies and personalized treatments.
- **Tumor Microenvironment:** We discover how tumors impair immune cells, which will jumpstart the creation of therapies that can fight hard-to-treat solid tumors.

Fuel bold research with robust infrastructure

The Parker Institute provides innovative tools and resources that aren't widely available so our researchers can do their most ambitious work.

- Our **clinical development team** works with our research institutions to lead larger, multi-site clinical trials. We adopted a single, streamlined agreement with our centers that expedites the approval of multi-center clinical trials, **saving both time and money**.
- The Parker Institute **takes a service-minded approach to working with our investigators on intellectual property**. We provide guidance at every step, from consulting on a patent application to connecting them to a prospective company. This collaborative process ensures that each new treatment or technology has the best chance to benefit patients.
- The **Parker Institute's in-house informatics team** – with expertise in immunology and cutting-edge machine learning, visualization and statistical methods – works closely with our investigators to **harness data collected from Parker Institute studies and draw conclusions to improve patient responses to treatments**.
- Our investigators gain **access to innovative technology and machines**. They also have access to **discounts on supplies and equipment** to ensure they have the tools they need to do the best research.

Key clinical trials and projects

 Opportunity	 Progress
Advance personalized cancer treatments through neoantigen discovery	The Parker Institute and the Cancer Research Institute launched a global collaboration of more than 40 leading cancer neoantigen research groups. The goal is to find the best algorithms to predict which cancer neoantigens can be recognized by and stimulate an immune response.
Investigate checkpoint inhibitor resistance in melanoma patients	Through our first trial to involve six research centers, we are taking a laser-focused approach to understand how combinations work in treating melanoma, as well as why some patients benefit from treatments while others do not.
Tackle pancreatic cancer with a new approach	In the first Parker Institute-led trial, we are leveraging our network of experts, using innovative technology and combining standard chemotherapy and two immunotherapy agents to treat pancreatic cancer, the nation's third deadliest cancer.
Use CRISPR technology for more efficient and effective cancer treatment	The Parker Institute is helping fund what we expect to be the first-in-human U.S. study of CRISPR technology, which will use new technology to engineer longer-lasting killer T-cells to treat patients with melanoma, sarcoma and multiple myeloma.
Collaborate for better responses to cancer therapy	The Parker Institute is partnering with MD Anderson Cancer Center and Seres Therapeutics to launch the first-of-its-kind microbiome-cancer immunotherapy trial for advanced melanoma patients based on a study published in <i>Science</i> .